Secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves overall survival in ...

NACT followed by ICS significantly improves 3-year PFS and OS in advanced ovarian cancer compared to chemotherapy alone. Patients undergoing NACT and ICS had better outcomes than those receiving only ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Susana M. Campos, MD, MPH, discusses new data from the TRUST trial, which were ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Neoadjuvant chemotherapy followed by interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) significantly improves progression-free survival (PFS) and overall survival ...

Cancer outcomes are largely measured in terms of disease-free survival or overall survival, which is highly dependent on timely diagnosis and access to treatment methods available within the country's ...

Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer. Among patients with platinum-sensitive peritoneal ...

Researchers found that adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival among patients with advanced ovarian cancer. The addition of retroperitoneal ...

The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

The preferred neoadjuvant chemotherapy regimen is a platinum-taxane doublet. The American Society of Clinical Oncology (ASCO) has updated its guidelines on neoadjuvant chemotherapy use in patients ...

High-volume hospitals with frequent NACT use had the lowest 90-day surgical mortality and longest 60-month survival. NACT reduced perioperative deaths in all hospital types, including those with low ...

The addition of an investigational immunotherapy to chemotherapy prolonged survival for women with advanced ovarian cancer, according to a topline data announcement. IMNN-001 (Imunon Inc.) is an IL-12 ...